Betnovate-N Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Betamethasone-17-valerate 0.1%, neomycin sulphate 0.5%

Indications/Uses

Relief of inflammatory & pruritic manifestations of steroid-responsive dermatoses eg, atopic, infantile & discoid eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses including lichen simplex & planus, seborrheic dermatitis, contact sensitivity & insect bites reactions. Management of secondary infected insect bites, anal & genital intertrigo.

Click to view Betnovate-N detailed prescribing information

Dosage/Direction for Use

Apply thinly to affected area once or bd for up to 7 days.

Click to view Betnovate-N detailed prescribing information

Overdosage

View Betnovate-N overdosage for action to be taken in the event of an overdose.

Contraindications

Rosacea, acne vulgaris, perioral dermatitis, pruritus w/o inflammation, perianal & genital pruritus, primary cutaneous viral infections. Primary infected skin lesions caused by infection w/ fungi or bacteria; primary or secondary infections due to yeast; secondary infections due to Pseudomonas or Proteus spp. Otitis externa w/ perforated eardrum. Large amounts or on large areas for prolonged periods. Childn <2 yr.

Click to view Betnovate-N detailed prescribing information

Special Precautions

Hypersensitivity. Discontinue use if infection occurs. Cushing's syndrome & reversible hypothalamic-pituitary-adrenal axis suppression. Pseudomembranous colitis. Increased risk of corticosteroidal systemic effects. Psoriasis; contact sensitisation; chronic leg ulcers; visual disturbances. Irreversible ototoxicity; nephrotoxicity. Use w/ occlusive dressings. Avoid contact w/ face & eyes. Avoid abrupt w/drawal. Renal impairment. Not recommended during pregnancy & lactation. Avoid long-term continuous therapy in childn <12 yr.

Click to view Betnovate-N detailed prescribing information

Use In Pregnancy & Lactation

Click to view Betnovate-N detailed prescribing information

Adverse Reactions

Pruritus, local skin burning/skin pain.

Click to view Betnovate-N detailed prescribing information

Drug Interactions

Inhibited metabolism by CYP3A4 inhibitors eg, ritonavir, itraconazole. Intensified & prolonged resp depressant effects of neuromuscular blocking agents. Possibility of cumulative toxicity w/ systemic aminoglycoside therapy.

Click to view Betnovate-N detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Betnovate-N detailed prescribing information

Storage

View Betnovate-N storage conditions for details to ensure optimal shelf-life.

Description

View Betnovate-N description for details of the chemical structure and excipients (inactive components).

Action

View Betnovate-N mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Topical Anti-Infectives with Corticosteroids

ATC Classification

D07CC01 - betamethasone and antibiotics ; Belongs to the class of potent (group III) corticosteroids, in combination with antibiotics. Used in the treatment of dermatological diseases.

Regulatory Classification

Presentation/Packing

Form

Betnovate-N cream

Packing/Price

15 g x 1's (RM19.05/tube)

Betnovate-N

betamethasone + neomycin

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma